Monday, 2 November 2020

Sun Pharma Q2 preview: Taro may hit revenue growth, trends in specialty portfolio key to watch

Sun Pharma Q2 preview: Taro may hit revenue growth, trends in specialty portfolio key to watch Sun Pharma#39;s key facility Halol continues to be under FDA issue which has slowed down new approvals.

from Moneycontrol Results News https://ift.tt/3l5KKQJ